PURPOSE: This study was designed to validate a fully automated adaptive planning (AAP) method which integrates automated recontouring and automated replanning to account for interfractional anatomical changes in prostate cancer patients receiving adaptive intensity modulated radiation therapy (IMRT) based on daily repeated computed tomography (CT)-on-rails images.
METHODS AND MATERIALS: Nine prostate cancer patients treated at our institution were randomly selected. For the AAP method, contours on each repeat CT image were automatically generated by mapping the contours from the simulation CT image using deformable image registration. An in-house automated planning tool incorporated into the Pinnacle treatment planning system was used to generate the original and the adapted IMRT plans. The cumulative dose-volume histograms (DVHs) of the target and critical structures were calculated based on the manual contours for all plans and compared with those of plans generated by the conventional method, that is, shifting the isocenters by aligning the images based on the center of the volume (COV) of prostate (prostate COV-aligned).
RESULTS: The target coverage from our AAP method for every patient was acceptable, while 1 of the 9 patients showed target underdosing from prostate COV-aligned plans. The normalized volume receiving at least 70 Gy V70, and the mean dose of the rectum and bladder were reduced by 8.9%, 6.4 Gy and 4.3%, 5.3 Gy, respectively, for the AAP method compared with the values obtained from prostate COV-aligned plans.
CONCLUSIONS: The AAP method, which is fully automated, is effective for online replanning to compensate for target dose deficits and critical organ overdosing caused by interfractional anatomical changes in prostate cancer.
Written by:
Li X, Quan EM, Li Y, Pan X, Zhou Y, Wang X, Du W, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. Are you the author?
Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Reference: Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):835-841.
doi: 10.1016/j.ijrobp.2013.04.014
PubMed Abstract
PMID: 23726001
UroToday.com Prostate Cancer Section
